Hepatotoxicity of chemotherapeutic agents: current state of the problem


Cite item

Full Text

Abstract

This review is devoted to the actual for the present day problem of the hepatotoxicity of chemotherapeutic agents. Liver is the most important organ essential for the maintaining of the body’s internal environment. For the present time there is observed the high level of the morbidity and mortality rate against the background of drug-induced liver lesions due to, in the first instance, the lack ofproper manner for the substitution of the liver function but transplantation. Liver deteriorations due to the administration of antitumor agents have no pathognomonic clinical or histological features that significantly embarrasses the execution of the differential diagnosis with liver disorders against the background of administration of other preparations, either associated with opportunistic infections or the progression of previously acquired pathology of the liver. In the article there is described the toxic influence on the liver of most often used in oncology chemotherapeutic agents - antimetabolites, alkylating agents, platinum compounds, epothilones, taxanes, vinca alkaloids, monoclonal antibodies, anthracycline antibiotics, topoisomerase and protein kinase inhibitors is described in this article. In the review there are summarized results of recent studies of etiology, pathogenesis, clinical features, diagnosis, prevention and treatment of chemotherapy induced hepatotoxicity. The special attention is given to recent discoveries in the area of pathogenesis of chemotherapy induced hepatotoxicity. However many moments remain to be still not studied completely, that offers perspectives for further research in this field.

About the authors

M. T Vatutin

M. Gorky Donetsk National Medical University; V.K. Gusak Institute of Emergency and Reconstructive Surgery

Donetsk, 83003, Ukraine

E. V Sklyannaya

M. Gorky Donetsk National Medical University; V.K. Gusak Institute of Emergency and Reconstructive Surgery

Donetsk, 83003, Ukraine

Mariam A. El-Khatib

M. Gorky Donetsk National Medical University; Center for Primary Health Care N5

Email: el-khatib.mariam@yandex.ru
Undergraduate of Department of Hospital Therapy of the M. Gorky Donetsk National Medical University Donetsk, 83003, Ukraine

S. V Starchenko

V.K. Gusak Institute of Emergency and Reconstructive Surgery

Donetsk, 83045, Ukraine;

M. V Makarova

V.K. Gusak Institute of Emergency and Reconstructive Surgery

Donetsk, 83045, Ukraine;

References

  1. Lewis J.H. Drug-induced liver disease. Med. Clin. N. Am. 2000; 84(5): 1275-311.
  2. Lee W. Drug-induced hepatotoxicity. N. Engl. J. Med. 2003; 349(5):474-85.
  3. Larrey D. Drug-induced liver diseases. J. Hepatol. 2000; 32 (1 Suppl.): 77-88.
  4. Лопаткина Т.Н., Бурневич Э.З. Лекарственные поражения печени. Врач. 2003; (12): 18-20.
  5. Helmy A. Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Aliment. Pharmacol. Ther. 2006; 23(1):11-25.
  6. Ishak K.G., Zimmerman H.J. Morphologic spectrums of drug-induced liver disease. Gastroenterol. Clin. N. Am. 1995; 24(4): 759-86.
  7. Navarro V.J., Senior J.R. Drug - related hepatotoxicity. N. Engl. J. Med. 2006; 354(7): 731-9.
  8. Faggioli P., De Paschale M., Tocci A., Luoni M., Fava S., De Paoli A. et al. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin’s lymphoma. Haematologica. 1997; 82(1): 38-42.
  9. Ghabril M., Chalasani N., Björnsson E. Drug-induced liver injury: a clinical update. Curr. Opin. Gastroenterol. 2010; 26(3): 222-6. doi: 10.1097/MOG.0b013e3283383c7c.
  10. Phillips K.A., Veenstra D.L., Oren E., Lee J. K., Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. J. A. M. A. 2001; 286(18): 2270-9.
  11. Kazuto T., Yukihiro S. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J. Gastroenterol. 2008; 14(44): 6774-85. doi: 10.3748/wjg.14.6774
  12. Aithal P.G., Day C.P. The natural history of histologically proved drug induced liver disease. Gut. 1999; 44(5): 731-5.
  13. Benichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J. Hepatol. 1990; 11(2): 272-6.
  14. Rodriguez-Frias E.A., Lee W.M. Cancer chemotherapy I: hepatocellular injury. Clin. Liver Dis. 2007; 11(3): 641-62.
  15. Lee W. Drug-induced hepatotoxicity. N. Engl. J. Med. 1995; 333(17): 1118-27.
  16. Курмуков И.А. Лекарственное поражение печени при лечении онкогематологических заболеваний. Клиническая онкогематология. 2010; (1): 60-7.
  17. Голованова Е.В. Возможности патогенетической терапии при лекарственных поражениях печени. Эффективная фармакотерапия. 2011; (3): 60-4.
  18. Torrisi J.M., Schwartz L.H., Gollub M.J., Ginsberg M.S., Bosl G.J., Hricak H. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology. 2011; 258(1): 41-56. doi: 10.1148/radiol.10092129.
  19. Markowitz J.S., Donovan J.L., DeVane C.L. Taylor R.M., Ruan Y., Wang J.S. et al. Effect of St John’s wort on drug metabolism by induction of cytochrome P4503A4 enzyme. J. A. M. A. 2003; 290(11): 1500-4.
  20. Ding X., Kaminsky L.S. Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 2003; 43: 149-73.
  21. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 346(16): 1221-31.
  22. van der Bol J.M., Mathijssen R.H., Loos W.J., Friberg L.E., van Schaik R.H., de Jonge M.J. et al. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J. Clin. Oncol. 2007; 25(19): 2719-26.
  23. Field K.M., Michael M. Part II: Liver function in oncology: towards safer chemotherapy use. Lancet Oncol. 2008; 9(12): 1181-90. doi: 10.1016/S1470-2045(08)70307-3.
  24. Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin. Liver Dis. 2002; 22(2): 137-44.
  25. Floyd J., Mirza I., Sachs B., Perry M.C. Hepatotoxicity of chemotherapy. Semin. Oncol. 2006; 33(1): 50-67.
  26. King P.D., Perry M.C. Hepatotoxicity of chemotherapy. Oncologist. 2001; 6(2): 162-76.
  27. Temple R. Hy’s law: predicting serious hepatotoxicity. Pharmacoepidemiol. Drug. Saf. 2006; 15(4): 241-3.
  28. Галимова С.Ф. Лекарственные поражения печени (часть I). Здравоохранение (Минск). 2013; (7): 41-50.
  29. Казюлин А.Н., Вельшер Л.З., Королева И.А. Возможности преодоления гепатотоксичности при проведении комбинированного и комплексного лечения рака молочной железы. Эффективная фармакотерапия. 2011; (3): 66-72.
  30. Chalasani N.P., Hayashi P.H., Bonkovsky H.L., Navarro V.J., Lee W.M., Fontana R.J. et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am. J. Gastroenterol. 2014; 109(7): 950-66. doi: 10.1038/ajg.2014.131.
  31. Norris W., Paredes A.H., Lewis J.H. Drug-induced liver injury in 2007. Curr. Opin. Gastroenterol. 2008; 24(3): 287-97. doi: 10.1097/MOG.0b013e3282f9764b.
  32. Lee W.M., Senior J.R. Recognizing drug induced liver injury: current problems, possible solutions. Toxicol. Pathol. 2005; 33: 155-64.
  33. Hoofnagle J.H. Drug-Induced Liver Injury Network (DILIN). Hepatology. 2004; 40(4):773.
  34. Ивашкин В.Т., Буеверов А.О. Патогенетическое и клиническое обоснование применения адеметионина в лечении больных с внутрипеченочным холестазом. Клинические перспективы гастроэнтерологии, гепатологии. 2009; (5): 24-9.
  35. Petrovic V., Teng S., Piquette-Miller M. Regulation of drug transporters during infection and inflammation. Mol. Interv. 2007; 7(2): 99-111.

Copyright (c) 2016 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies